Merck & Co. (MRK)
(Delayed Data from NYSE)
$101.88 USD
-0.44 (-0.43%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$101.88 USD
-0.44 (-0.43%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Zacks News
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Will Bristol Myers (BMY) Gain From New Drugs' Label Expansion?
by Zacks Equity Research
Label expansion of Bristol Myers' (BMY) new drugs should help it somewhat combat the decline in Revlimid sales due to generic competition.
Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates
by Kinjel Shah
J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.
3 Reasons to Buy Healthcare Stocks in the Current Market Environment
by Andrew Rocco
Healthcare stocks are currently providing investors with an attractive way to counterbalance a portfolio overexposed to tech. In general, healthcare stocks have lower betas, are more defensive, and have cleaner balance sheets.
AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal
by Zacks Equity Research
Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.
Merck (MRK) Stock Moves -0.04%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $108.83, marking a -0.04% move from the previous day.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod
by Zacks Equity Research
The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.
Merck (MRK), Seagen Drug Combo Gets FDA Nod for Bladder Cancer
by Zacks Equity Research
The combination of Merck's (MRK) Keytruda and Seagen's (SGEN) Padcev is the first approved immunotherapy and an antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMV
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $105.53, marking a -1.31% move from the previous day.
GSK's Jemperli Effective Against First-Line Endometrial Cancer
by Zacks Equity Research
A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV
Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug
by Zacks Equity Research
Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Nuveen ESG Large-Cap Value ETF (NULV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NULV
Sanofi (SNY) Moves 6.0% Higher: Will This Strength Last?
by Zacks Equity Research
Sanofi (SNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Add Novo (NVO) Stock to Your Portfolio
by Zacks Equity Research
Novo (NVO), a top-ranked stock at present, enjoys a strong foothold in the Diabetes Care market with increasing market shares driven by Rybelsus, Ozempic and Victoza's strong performance.
The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton
by Zacks Equity Research
Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton are part of the Zacks top Analyst Blog.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $105.54, marking a -0.29% move from the previous day.
Top Research Reports for Merck, Intel & MercadoLibre
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Intel Corporation (INTC) and MercadoLibre, Inc. (MELI).
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP